Alpha DNA Investment Management LLC Has $947,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 16th, 2023

Alpha DNA Investment Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,359 shares of the company’s stock after purchasing an additional 328 shares during the quarter. Alpha DNA Investment Management LLC’s holdings in Johnson & Johnson were worth $947,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lincoln Capital Corp increased its stake in shares of Johnson & Johnson by 15.9% in the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after acquiring an additional 183 shares during the last quarter. Ieq Capital LLC boosted its holdings in shares of Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares during the last quarter. RFG Advisory LLC lifted its holdings in Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after purchasing an additional 594 shares during the last quarter. Willis Investment Counsel lifted its holdings in Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after purchasing an additional 1,358 shares during the last quarter. Finally, FDx Advisors Inc. lifted its holdings in Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after purchasing an additional 153 shares during the last quarter. 67.94% of the stock is owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $165.84 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The stock’s 50-day moving average is $157.46 and its 200 day moving average is $167.02. The stock has a market cap of $431.90 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 2.83 and a beta of 0.53. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period in the previous year, the company posted $2.13 earnings per share. The firm’s revenue was down 4.4% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Piper Sandler cut their price target on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Atlantic Securities increased their price objective on Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Guggenheim assumed coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Finally, StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.